Stock Analysis, Dividends, Split History

CRSP / CRISPR Therapeutics AG financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price36.04
Volume615,300.00
Market Cap ($M)1,891.10
Enterprise Value ($M)1,770.23
Book Value ($M)265.15
Book Value / Share5.57
Price / Book6.68
NCAV ($M)242.57
NCAV / Share5.10
Price / NCAV7.30
Share Statistics
Common Stock Shares Outstanding 40,592,248
Preferred Stock Shares Outstanding 0
Common Shares Outstanding 46,976,000
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.36
Return on Assets (ROA)-0.20
Return on Equity (ROE)-0.29
Balance Sheet (mrq) ($M)
Assets353.13
Liabilities87.98
Quick Ration/a
Current Ratio17.89
Income Statement (mra) ($M)
Revenues40,997,000.00
Revenue From Related Parties4,760,000.00
Operating Income-64.65
Net Income-68.36
Earnings Per Share Basic-1.71
Earnings Per Share Basic And Diluted-1.71
Earnings Per Share Diluted-1.71
Cash Flow Statement (mra) ($M)
Cash From Operations-70.10
Cash from Investing-8.31
Cash from Financing-70.10
Identifiers and Descriptors
CUSIPH17182108
Central Index Key (CIK)1674416
Industry Groups

Split History

Stock splits are used by CRISPR Therapeutics AG to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related News Stories

Biotech Analysis Central Pharma News: Roche's Deal, AcelRX Panel Vote, Crispr And Vertex Hold Removal

2018-10-17 seekingalpha
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry.

Long-Term Outlook For Vertex Pharmaceuticals: October 13, 2018

2018-10-14 seekingalpha
Vertex Pharmaceuticals has been a rising star in the biotech field, with excellent price action for well over a year now (excluding the latest dip).

3 High-Reward Stocks From 3 Emerging Trends

2018-10-13 investorplace
Think of the extraordinary change someone born in 1900 would have seen over a long life. They would see horses in city streets as a child and grow up to see those same streets full of cars. They would see the invention of the radio, the airplane, the fax machine and air conditioning. And the list of big changes goes on. (8-4)

Long-Term Outlook For CRISPR Therapeutics: October 11, 2018

2018-10-12 seekingalpha
CRISPR Therapeutics got some good news this week with a clinical hold lifted, but it has a long way to go to make up for the share performance of late. (0-2)

Merrimack (MACK) Focuses on Early Stage Pipeline and Cost Cuts

2018-10-11 zacks
On Oct 10, we issued an updated research report on Merrimack Pharmaceuticals, Inc. (MACK - Free Report) . (16-0)

CUSIP: H17182108